Literature DB >> 7876251

Studies on the structure and function of glycosylated and nonglycosylated neu differentiation factors. Similarities and differences of the alpha and beta isoforms.

H S Lu1, D Chang, J S Philo, K Zhang, L O Narhi, N Liu, M Zhang, J Sun, J Wen, D Yanagihara.   

Abstract

Comparative analyses of both glycosylated and nonglycosylated neu differentiation factor (NDF) isoforms revealed significant similarities and differences of their overall structures and functions. Biophysical analyses confirmed that all NDF isoforms are monomeric, but have an extended ellipsoidal shape in solution. All full-length NDFs are similar in secondary and tertiary structures and they contain no alpha-helix but are abundant in beta-strand structures. A small NDF fragment containing only the epidermal growth factor domain is also rich in beta-strand structures, but exhibits tertiary structure different from the long NDF forms. Monoclonal antibodies that selectively recognize epidermal growth factor domains of human NDF-alpha and -beta can specifically bind the respective NDF-alpha and -beta isoforms independent of NDF origins. Western blot analysis and quantitative binding assays further identify that an NDF preparation produced naturally from Rat1-EJ cells contains both alpha and beta isoforms in a 3 to 2 ratio. In receptor-binding competition experiments, human and rat NDF-beta isoforms have higher affinity than NDF-alpha isoforms. NDF-beta isoforms can dramatically enhance the stimulation of DNA synthesis for transfected NIH3T3 cells that overexpress HER-3 and HER-4 receptors, while NDF-alpha isoforms can only stimulate proliferation of HER-4-transfected cells with lower activity. Taken together, NDF-alpha and -beta isoforms share similar gross protein conformations but are biologically distinct.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7876251     DOI: 10.1074/jbc.270.9.4784

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Soluble Neuregulin and Schwann Cell Myelination: a Therapeutic Potential for Improving Remyelination of Adult Axons.

Authors:  Neeraja Syed; Haesun A Kim
Journal:  Mol Cell Pharmacol       Date:  2010

2.  Soluble neuregulin-1 has bifunctional, concentration-dependent effects on Schwann cell myelination.

Authors:  Neeraja Syed; Kavya Reddy; David P Yang; Carla Taveggia; James L Salzer; Patrice Maurel; Haesun A Kim
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

3.  Specific regulation of NRG1 isoform expression by neuronal activity.

Authors:  Xihui Liu; Ryan Bates; Dong-Min Yin; Chengyong Shen; Fay Wang; Nan Su; Sergei A Kirov; Yuling Luo; Jian-Zhi Wang; Wen-Cheng Xiong; Lin Mei
Journal:  J Neurosci       Date:  2011-06-08       Impact factor: 6.167

Review 4.  Neuregulins in glial cells.

Authors:  T D Raabe; A Francis; G H DeVries
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

Review 5.  Signalling between microvascular endothelium and cardiomyocytes through neuregulin.

Authors:  Emily M Parodi; Bernhard Kuhn
Journal:  Cardiovasc Res       Date:  2014-01-29       Impact factor: 10.787

6.  Structure and function of the N-linked glycans of HBP/CAP37/azurocidin: crystal structure determination and biological characterization of nonglycosylated HBP.

Authors:  L F Iversen; J S Kastrup; S E Bjørn; F C Wiberg; I K Larsen; H J Flodgaard; P B Rasmussen
Journal:  Protein Sci       Date:  1999-10       Impact factor: 6.725

7.  The cellular response to neuregulins is governed by complex interactions of the erbB receptor family.

Authors:  D J Riese; T M van Raaij; G D Plowman; G C Andrews; D F Stern
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

Review 8.  Roles for neuregulins in human cancer.

Authors:  Christophe Stove; Marc Bracke
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

9.  Regulation of the Drosophila epidermal growth factor-ligand vein is mediated by multiple domains.

Authors:  Timothy Donaldson; Shu-Huei Wang; Thomas L Jacobsen; Bruce Schnepp; Jessica Price; Amanda Simcox
Journal:  Genetics       Date:  2004-06       Impact factor: 4.562

Review 10.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.